Wall S J, Yasuda R P, Li M, Ciesla W, Wolfe B B
Department of Pharmacology, Georgetown University School of Medicine, Washington, DC.
J Pharmacol Exp Ther. 1992 Aug;262(2):584-8.
The regulation of individual muscarinic receptor subtypes in rat cerebral cortex/dorsal hippocampus was examined following 14-day administration of the nonselective antagonist atropine. Total muscarinic receptor density increased 24%, from 2196 fmol/mg to 2722 fmol/mg. The nature of this increase was examined using a panel of antisera selective for the m1 to m5 muscarinic receptors. Thus, 97% of all cortical/hippocampal receptors were accounted for by immunoprecipitation. Three subtypes were observed to increase significantly in density: m1 receptor from 824 to 982 fmol/mg (19%, P less than .05); m2 receptor from 476 to 519 fmol/mg (9%, N.S.); m3 receptor from 259 to 438 fmol/mg (69%, P less than .001); m4 receptor from 574 to 638 fmol/mg (11%, P less than .05); and the m5 receptor from 23 to 38 fmol/mg (65%, N.S.). Receptors coupled to the hydrolysis of phosphoinositides (m1, m3, m5) appeared to be preferentially up-regulated (32% over control levels, P less than .001) compared with those coupled to the inhibition of adenylyl cyclase (m2, m4; 10% over control levels, P less than .05). The absolute density of the molecularly defined m1 and m4 receptors, which reportedly possess the highest affinity for pirenzepine (M1), increased 16% (P less than .05), whereas the density of receptors having the lowest affinity for pirenzepine (m2, m3 and m5) increased 31% (P less than .001) with atropine treatment. When the increase in total receptor density was examined with [3H]pirenzepine, the 16% elevation in high-affinity (m1 and m4) sites was not detected.(ABSTRACT TRUNCATED AT 250 WORDS)
在给予非选择性拮抗剂阿托品14天后,检测了大鼠大脑皮层/背侧海马中各毒蕈碱受体亚型的调节情况。毒蕈碱受体总密度增加了24%,从2196飞摩尔/毫克增至2722飞摩尔/毫克。使用一组对m1至m5毒蕈碱受体具有选择性的抗血清来研究这种增加的性质。因此,通过免疫沉淀法可检测到所有皮层/海马受体中的97%。观察到三种亚型的密度显著增加:m1受体从824飞摩尔/毫克增至982飞摩尔/毫克(19%,P<0.05);m2受体从476飞摩尔/毫克增至519飞摩尔/毫克(9%,无显著性差异);m3受体从259飞摩尔/毫克增至438飞摩尔/毫克(69%,P<0.001);m4受体从574飞摩尔/毫克增至638飞摩尔/毫克(11%,P<0.05);m5受体从23飞摩尔/毫克增至38飞摩尔/毫克(65%,无显著性差异)。与那些与腺苷酸环化酶抑制偶联的受体(m2、m4;比对照水平高10%,P<0.05)相比,与磷酸肌醇水解偶联的受体(m1、m3、m5)似乎优先上调(比对照水平高32%,P<0.001)。据报道,对哌仑西平(M1)具有最高亲和力的分子定义的m1和m4受体的绝对密度增加了16%(P<0.05),而对哌仑西平具有最低亲和力的受体(m2、m3和m5)的密度在阿托品治疗后增加了31%(P<0.001)。当用[3H]哌仑西平检测总受体密度的增加时,未检测到高亲和力(m1和m4)位点升高16%的情况。(摘要截短于250字)